Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges.
1/5 보강
Breast cancer, the most diagnosed malignancy globally, poses a significant health burden, with approximately 2.3 million new cases and 700,000 deaths annually.
APA
Sheela IJ, Jeya Ranchani AA, et al. (2026). Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges.. Clinical breast cancer, 26(3), 54-64. https://doi.org/10.1016/j.clbc.2026.01.004
MLA
Sheela IJ, et al.. "Breast Cancer Vaccines: A Review of Emerging Opportunities and Persistent Challenges.." Clinical breast cancer, vol. 26, no. 3, 2026, pp. 54-64.
PMID
41687244 ↗
Abstract 한글 요약
Breast cancer, the most diagnosed malignancy globally, poses a significant health burden, with approximately 2.3 million new cases and 700,000 deaths annually. Breast cancer vaccines represent an innovative approach to prevention and treatment, harnessing the immune system to target tumor-specific antigens such as α-lactalbumin, HER2, and MUC1. Prophylactic vaccines aim to reduce risk in high-risk groups like BRCA1/2 mutation carriers, while therapeutic vaccines, particularly for triple-negative breast cancer, stimulate T-cell responses to combat aggressive tumors. Advances in mRNA technology, nanoparticle delivery, and neoantigen identification enhance vaccine precision and efficacy. However, challenges including tumor heterogeneity, immune evasion, and production scalability limit clinical success. Ongoing phase I and II trials explore combination therapies with checkpoint inhibitors and antibody-drug conjugates to overcome these barriers. This review examines the current landscape, mechanisms, and challenges of breast cancer vaccines, highlighting their potential to transform oncology through personalized, less invasive strategies.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.